Peyton J Tebon

Dr. Peyton J Tebon

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Materials Today Bio
Verified
Journal Article
Open access
JNJ. Ni
J. Ni
HLH. Ling
H. Ling
SZS. Zhang
S. Zhang
ZWZ. Wang
Z. Wang
ZPZ. Peng
Z. Peng
Ali  KhademhosseiniAli Khademhosseini
Ali Khademhosseini
Three-dimensional (3D) printing technology has received great attention in the past decades in both academia and industry because of its advantages such as customized fabrication, low manufacturing cost, unprecedented capability for complex geometry, and short fabrication period. 3D printing of metals with controllable structures represents a state-of-the-art technology that enables the development of metallic implants for biomedical applications. This review discusses currently existing 3D printing techniques and their applications in developing metallic medical implants and devices. Perspective about the current challenges and future directions for development of this technology is also presented.

1 April 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
KAKhadijeh Ashtari
Khadijeh Ashtari
HNHojjatollah Nazari
Hojjatollah Nazari
HKHyojin Ko
Hyojin Ko
PTPeyton J Tebon
Peyton J Tebon
MAMasoud Akhshik
Masoud Akhshik
Ali  KhademhosseiniAli Khademhosseini
Ali Khademhosseini

6 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
PTPeyton J Tebon
Peyton J Tebon
BWBowen Wang
Bowen Wang
AMAlexander L. Markowitz
Alexander L. Markowitz
ADArdalan Davarifar
Ardalan Davarifar
BTBrandon L. Tsai
Brandon L. Tsai
ASAlice Soragni
Alice Soragni
High throughput drug screening is an established approach to investigate tumor biology and identify therapeutic leads. Traditional platforms use two-dimensional cultures which do not accurately reflect the biology of human tumors. More clinically relevant model systems such as three-dimensional tumor organoids can be difficult to scale and screen. Manually seeded organoids coupled to destructive endpoint assays allow for the characterization of treatment response, but do not capture transitory changes and intra-sample heterogeneity underlying clinically observed resistance to therapy. We present a pipeline to generate bioprinted tumor organoids linked to label-free, time-resolved imaging via high-speed live cell interferometry (HSLCI) and machine learning-based quantitation of individual organoids. Bioprinting cells gives rise to 3D structures with unaltered tumor histology and gene expression profiles. HSLCI imaging in tandem with machine learning-based segmentation and classification tools enables accurate, label-free parallel mass measurements for thousands of organoids. We demonstrate that this strategy identifies organoids transiently or persistently sensitive or resistant to specific therapies, information that could be used to guide rapid therapy selection.

3 January 2019 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
WSWujin Sun
Wujin Sun
ZLZhimin Luo
Zhimin Luo
JLJunmin Lee
Junmin Lee
HKHanjun Kim
Hanjun Kim
KLKangJu Lee
KangJu Lee
Ali  KhademhosseiniAli Khademhosseini
Ali Khademhosseini

1 July 2019 in Progress in Biomedical Engineering
Verified
Journal Article
Closed access
KFKirsten Fetah
Kirsten Fetah
PTPeyton J Tebon
Peyton J Tebon
MGMarcus J Goudie
Marcus J Goudie
JEJames Eichenbaum
James Eichenbaum
LRLi Ren
Li Ren
Ali  KhademhosseiniAli Khademhosseini
Ali Khademhosseini
Understanding complex cell–cell interactions and physiological microenvironments is critical for the development of new therapies for treating human diseases. Current animal models fail to accurately predict success of therapeutic compounds and clinical treatments. Advances in biomaterials, engineering, and additive manufacturing have led to the development of printed tissues, lab-on-chip devices, and, more recently, organ-on-chip systems. These technologies have promising applications for the fabrication of more physiologically representative human tissues and can be used for high-throughput testing of human cells and organoids. These organ-on-chip systems can be fabricated with integrated fluidics to allow for the precise control and manipulation of cellular microenvironments with multiple cell types. Further control over these cellular environments can be achieved with bioprinting, allowing for three-dimensional (3D) printing of multiple materials and cell types to provide precisely controlled structures manufactured in a one-step process. As cell behavior is highly dependent on the physical and chemical properties of the environment, the behavior of cells in two-dimensional and 3D culture systems varies drastically. Providing devices that can support long-term cell culture and controlled stimulation of 3D culture systems will have a profound impact on the study of physiological processes and disease, as well as the development of new therapies. This review highlights recent advances in organ-on-chip systems and 3D bioprinting techniques for the development of in vitro physiological models.

10 March 2021 in Biofabrication
Verified
Journal Article
Closed access
TPTyler Potyondy
Tyler Potyondy
JUJorge Alfredo Uquillas
Jorge Alfredo Uquillas
PTPeyton J Tebon
Peyton J Tebon
BBBatzaya Byambaa
Batzaya Byambaa
AHAnwarul Hasan
Anwarul Hasan
Nureddin AshammakhiNureddin Ashammakhi
Nureddin Ashammakhi
The musculoskeletal system is essential for maintaining posture, protecting organs, facilitating locomotion, and regulating various cellular and metabolic functions. Injury to this system due to trauma or wear is common, and severe damage may require surgery to restore function and prevent further harm. Autografts are the current gold standard for the replacement of lost or damaged tissues. However, these grafts are constrained by limited supply and donor site morbidity. Allografts, xenografts, and alloplastic materials represent viable alternatives, but each of these methods also has its own problems and limitations. Technological advances in three-dimensional (3D) printing and its biomedical adaptation, 3D bioprinting, have the potential to provide viable, autologous tissue-like constructs that can be used to repair musculoskeletal defects. Though bioprinting is currently unable to develop mature, implantable tissues, it can pattern cells in 3D constructs with features facilitating maturation and vascularization. Further advances in the field may enable the manufacture of constructs that can mimic native tissues in complexity, spatial heterogeneity, and ultimately, clinical utility. This review studies the use of 3D bioprinting for engineering bone, cartilage, muscle, tendon, ligament, and their interface tissues. Additionally, the current limitations and challenges in the field are discussed and the prospects for future progress are highlighted.